FDA-cleared profile

PRAEVAorta®2

Nurea · CT/CTA · FDA-cleared (510(k))

Authorized purpose: PRAEVAorta 2 assists clinical specialists, physicians, and other licensed practitioners with automatic vascular segmentation and maximum-diameter measurement on adult CT images; results require clinical assessment and physician validation when obtained by a non-physician.

Clinical role
Measurement or quantification
Images and patients
CT/CTA · Heart/Cardiovascular
Key limitation
Keep in mind: Adult use. Results are not a standalone basis for clinical decisions and do not replace clinical assessment. Results obtained by non-physicians require physician validation.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: PRAEVAorta 2 assists clinical specialists, physicians, and other licensed practitioners with automatic vascular segmentation and maximum-diameter measurement on adult CT images; results require clinical assessment and physician validation when obtained by a non-physician.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Heart/Cardiovascular Input: DICOM CT images containing blood vessels; the assessment included contrast and noncontrast scans, preoperative and postoperative cases, and aortic stent grafts.
  • Who uses it?Intended users: Clinical specialists, physicians, and other licensed practitioners; non-physician results must be validated by the responsible physician.
  • What does the software produce?Output: Vascular reconstruction and aneurysm/thrombus segmentation; diameters, volumes, angles, and distances between anatomical points; PDF, JSON, DICOM SC reports, and DICOM GSPS.
  • What is its most important limitation?Key limitation: Adult use. Results are not a standalone basis for clinical decisions and do not replace clinical assessment. Results obtained by non-physicians require physician validation.

Clinical takeaway. Clinical role: PRAEVAorta 2 assists clinical specialists, physicians, and other licensed practitioners with automatic vascular segmentation and maximum-diameter measurement on adult CT images; results require clinical assessment and physician validation when obtained by a non-physician.

Evidence takeaway. Evidence from the reviewed source record: FDA technical assessment used 159 independent adult CT cases from the United States, France, and Canada, with four vascular surgeons providing manual measurement reference. Maximum orthogonal aortic-diameter mean absolute error was 2.04 mm (95% CI 1.75-2.34); 96.9% of values were within 5 mm. The latter is measurement agreement, not disease-detection accuracy.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
PRAEVAorta 2 assists clinical specialists, physicians, and other licensed practitioners with automatic vascular segmentation and maximum-diameter measurement on adult CT images; results require clinical assessment and physician validation when obtained by a non-physician.
  • Exact FDA submission
  • Checked 2026-09-05
Workflow role
Measurement or quantification
  • Exact FDA submission
  • Checked 2026-09-05
Required input
DICOM CT images containing blood vessels; the assessment included contrast and noncontrast scans, preoperative and postoperative cases, and aortic stent grafts.
  • Exact FDA submission
  • Checked 2026-09-05
Output and clinician action
Vascular reconstruction and aneurysm/thrombus segmentation; diameters, volumes, angles, and distances between anatomical points; PDF, JSON, DICOM SC reports, and DICOM GSPS.
  • Exact FDA submission
  • Checked 2026-09-05
Care setting
Adults in healthcare institutions, including clinics, hospitals, residential care, and long-term care services.
  • Exact FDA submission
  • Checked 2026-09-05
Intended users
Clinical specialists, physicians, and other licensed practitioners; non-physician results must be validated by the responsible physician.
  • Exact FDA submission
  • Checked 2026-09-05
Limitations
Adult use. Results are not a standalone basis for clinical decisions and do not replace clinical assessment. Results obtained by non-physicians require physician validation.
  • Exact FDA submission
  • Checked 2026-09-05
Evidence summary
FDA technical assessment used 159 independent adult CT cases from the United States, France, and Canada, with four vascular surgeons providing manual measurement reference. Maximum orthogonal aortic-diameter mean absolute error was 2.04 mm (95% CI 1.75-2.34); 96.9% of values were within 5 mm. The latter is measurement agreement, not disease-detection accuracy.
  • Exact FDA submission
  • Checked 2026-09-05

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA technical assessment used 159 independent adult CT cases from the United States, France, and Canada, with four vascular surgeons providing manual measurement reference. Maximum orthogonal aortic-diameter mean absolute error was 2.04 mm (95% CI 1.75-2.34); 96.9% of values were within 5 mm. The latter is measurement agreement, not disease-detection accuracy.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Reported sensitivity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-05

Reviewed testing reports diameter error and agreement; no disease-detection sensitivity with a defined endpoint was established.

Reported specificity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-05

Reviewed testing reports diameter error and agreement; no disease-detection specificity with a defined endpoint was established.

Maximum orthogonal aortic-diameter mean absolute error

2.04 mm

  • EndpointAgreement with four vascular surgeons' manual reference measurements; acceptance required at least 96% within 5 mm and correlation above 0.90.
  • Population159 adult CT cases: 81 US, 40 France, 38 Canada; 95 preoperative and 64 postoperative, 62 with aortic stent grafts; contrast and noncontrast scans.
  • Tested versionPRAEVAorta 2 submitted in K243859; build not stated in reviewed text

PRAEVAorta 2 FDA technical measurement assessment

  • DesignStandalone technical comparison against four vascular surgeons' manual measurements
  • PopulationAdult contrast and noncontrast CT before or after vascular intervention
  • Scopeexact submission
  • Tested versionPRAEVAorta 2 in K243859; build not reported
  • Samplen=159
  • IndependenceIndependence not established

K243859

Cases were separate from AI training. FDA regulatory testing, not an independent publication.

Validation Study Comparing Artificial Intelligence for Fully Automatic Aortic Aneurysms Segmentation and Diameter Measurements on Contrast and Noncontrast Enhanced Computed Tomography

  • DesignSingle-center retrospective comparative study
  • Population120 CT scans, equally divided between CTA and noncontrast CT, in aneurysm-repair and control cases; two vascular surgeons provided semiautomatic comparison measurements.
  • Scopeproduct family
  • Tested versionPRAEVAorta2; exact build and K243859 equivalence not established
  • Samplen=120
  • Sites1
  • IndependenceIndependence not established

PMID:40480487 · DOI:10.1016/j.avsg.2025.05.045

Abstract and affiliations reviewed; a Nurea-affiliated author is listed. Numeric results are not transferred to K243859. This is scan count, not unique-patient count.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM CT images containing blood vessels; the assessment included contrast and noncontrast scans, preoperative and postoperative cases, and aortic stent grafts.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-05 · FDA 510(k) K243859: PRAEVAorta 2

  2. Routing

    Source context, not route validation: Server software accessed through APIs, with a web client, gateway/PACS client, integrating solution, or marketplace; PDF, JSON, DICOM SC, and DICOM GSPS outputs.

    Scope: Exact FDA submission. Specific PACS versions and supported transactions require local confirmation.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-05 · FDA 510(k) K243859: PRAEVAorta 2

  3. AI processing

    Source context, not route validation: The exact FDA package describes PRAEVAorta 2 as server software usable through APIs that is cloud based or can be installed on premises, with a client software (such as a web client) providing the interface to send images and receive results. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "This software is cloud based or can be installed on premises. PRAEVAorta®2 is a server software usable through APIs." … "The client aims to provide a user interface to send images and receive the analysis results. It can either be a web client". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA 510(k) K243859: PRAEVAorta 2

  4. Returned objects

    Source context, not route validation: Vascular reconstruction and aneurysm/thrombus segmentation; diameters, volumes, angles, and distances between anatomical points; PDF, JSON, DICOM SC reports, and DICOM GSPS.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-05 · FDA 510(k) K243859: PRAEVAorta 2

  5. Viewer/worklist/report

    Unresolved route: Vascular reconstruction and aneurysm/thrombus segmentation; diameters, volumes, angles, and distances between anatomical points; PDF, JSON, DICOM SC reports, and DICOM GSPS.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-05 · FDA 510(k) K243859: PRAEVAorta 2

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes PRAEVAorta 2 as server software usable through APIs that is cloud based or can be installed on premises, with a client software (such as a web client) providing the interface to send images and receive results. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "This software is cloud based or can be installed on premises. PRAEVAorta®2 is a server software usable through APIs." … "The client aims to provide a user interface to send images and receive the analysis results. It can either be a web client". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
Server software accessed through APIs, with a web client, gateway/PACS client, integrating solution, or marketplace; PDF, JSON, DICOM SC, and DICOM GSPS outputs.
  • Exact FDA submission
  • Checked 2026-09-05

Specific PACS versions and supported transactions require local confirmation.

API deployment and reports

Cloud or on-premises server deployment through APIs, with PDF, JSON, DICOM SC, and DICOM GSPS results.

exact submission · checked 2026-09-05

Current vendor workflow

Nurea describes automatic arterial reconstruction integrated with PACS, workstations, and imaging software, including lumen/thrombus differentiation and longitudinal follow-up.

product family · checked 2026-09-05

Current product-family description. Local compatibility and any features beyond the FDA indications require separate confirmation.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K243859
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Anatomy
Heart/Cardiovascular
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05

Catalog category retained; exact scope includes aorta and iliac vessels in thoraco-abdomino-pelvic CT.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-08-29
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-05Last searched
28Fields reviewed
12Source classes checked
2Screened PubMed leads
2Screened trial leads
0Unreviewed FDA recall leads

All stored metadata screened. PMID 40480487 abstract supports a contextual PRAEVAorta2 study, without exact-build linkage. PMID 41321026 concerns carotid-lesion segmentation; exact aortic-product applicability not established and no results promoted. Live registry content identifies NCT05287828 and NCT05920317 as Nurea/PRAEVAorta-family studies; no posted results or exact K243859 build linkage were established, so neither is promoted as exact-submission clinical performance. The current discovery snapshot contains 2 PubMed and 2 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda decision material, vendor product page, literature index, peer reviewed literature, trial registry, fda device recall, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-05 - Exact FDA submission

    The reviewed official product page offers a demo without scoped pricing. Licensing, processing volume, client/integration costs, support, and cloud/on-premises terms require quotation; procurement research is incomplete.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "Nurea PRAEVAorta reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-05 - Exact FDA submission

    FDA functional data-security testing and general vendor language do not establish a current scoped attestation, hosting region, retention policy, or access-control configuration.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-05 - Exact FDA submission

    Training of reference readers in the FDA study is not a customer onboarding commitment. Current user training and support terms remain unverified.

  • Monitoring: Not verified - checked 2026-09-05 - Exact FDA submission

    Local acceptance, output correction, update control, and incident escalation require vendor and site documentation.

8 sources - 3 history items

Source ledger

  1. FDA 510(k) K243859: PRAEVAorta 2

    U.S. Food and Drug Administration - Published 2025-08-29 - Accessed 2026-09-05

    Scope: identity, purpose, clinicalUse, modality, anatomy, input, output, limitations, integration, deployment, evidenceSummary, evidenceMetrics

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PRAEVAorta®2 model card (K243859)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. PRAEVAorta 2 decision support software for vascular diseases

    Nurea - Accessed 2026-09-05

    Scope: productFamilyWorkflow, implementationCapabilities

  8. Validation Study Comparing Artificial Intelligence for Fully Automatic Aortic Aneurysms Segmentation and Diameter Measurements on Contrast and Noncontrast Enhanced Computed Tomography

    Annals of Vascular Surgery; abstract via PubMed - Published 2025-06-04 - Accessed 2026-09-05

    Scope: contextualEvidenceStudy

Research history

  1. K243859 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K252217

CT VScore+

Canon Medical Informatics, Inc.

Authorized purpose: CT VScore+ evaluates calcified coronary lesions on ECG-gated, non-contrast cardiac CT in patients aged 30 years or older, automatically generating coronary calcium scores and highlighted calcium segmentation for qualified clinical review.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-11-28
FDA-cleared K251027

cvi42 Coronary Plaque Software Application

Circle Cardiovascular Imaging, Inc.

Authorized purpose: cvi42 Coronary Plaque supports qualified professionals with viewing, post-processing, and qualitative and quantitative evaluation of adult cardiac CT DICOM images to assess the presence and extent of coronary plaques and stenoses in CCTA for CAD or suspected CAD.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-10-27
FDA-cleared K251656

Careverse CoronaryDoc (Careverse CoronaryDoc)

Careverse Technology Pte. Ltd.

Authorized purpose: Careverse CoronaryDoc is a web-based tool for trained medical professionals to view and analyze CCTA CT data for coronary plaques and stenosis, with coronary measurements, visualization, automated plaque and stenosis outputs, and structured reporting for physician review.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-09-04

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history